Meeting
2011 ASCO Annual Meeting
Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.
Authors
A. A. Adjei
Roswell Park Cancer Institute, Buffalo, NY
A. A. Adjei , J. A. Sosman , R. E. Martell , G. K. Dy , L. W. Goff , W. W. Ma , L. Horn , G. J. Fetterly , S. A. Michael , J. A. Means , F. Chai , M. Lamar , G. M. Strauss , W. Chiang , J. Jarboe , B. E. Schwartz , I. Puzanov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
New Targets, New Technologies
Clinical Trial Registration Number
NCT00827177
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3034)
Abstract #
3034
Poster Bd #
10G
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.
First Author: Robert E. Martell
Poster
2012 ASCO Annual Meeting
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.
First Author: Julie Ann Means-Powell
Poster
2024 ASCO Annual Meeting
Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).
First Author: Shen Zhao
Poster
2015 ASCO Annual Meeting
CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors.
First Author: Kristen Renee Spencer